Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could tame Hormone-Driven high blood pressure

NCT ID NCT07007793

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a new drug called baxdrostat in about 250 adults with primary aldosteronism, a condition where the adrenal glands make too much aldosterone, causing high blood pressure. Participants take baxdrostat or a placebo daily for 8 weeks to see if it lowers blood pressure and restores normal hormone levels. The goal is to find a better treatment option for this specific form of high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants must be ≥ 18 years of age * Participants with a documented diagnosis of PA that fulfils the criteria defined in the 2016 or 2025 Endocrine Society Guidelines. * Participants willing and able to cease dosing of MRA or potassium sparing diuretics per study requirement for participants taking an MRA or potassium sparing diuretic at Screening. * eGFR ≥ 45 mL/min/1.73m2 at Screening * Serum potassium level ≥ 3.0 and \< 5.0 mmol/L at Screening determined as per the central laboratory. * Have a stable regimen of antihypertensive medications for at least 4 weeks prior to randomisation * Mean seated SBP on AOBPM of ≥ 135 mmHg and ≤ 170 mmHg and mean DBP of ≤ 105 mmHg. * Serum potassium (local lab) \> 3.0 mmol/L at randomization. Exclusion Criteria: \- If not taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP \> 170 mmHg or mean seated DBP \>105 mmHg (on AOBPM). If taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP \> 160 mmHg or mean seated DBP ≥ 100 mmHg. * Previous surgical intervention for an adrenal adenoma or have a planned adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study. * Has the following known secondary causes of HTN: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation. * Serum sodium level \< 135 mmol/L at Screening, determined as per central laboratory. * New York Heart Association functional HF class IV at Screening. * Persistent atrial fibrillation. * Treatment with any MRA or potassium-sparing diuretic within 2 weeks prior to Randomisation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary hyperaldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 6 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    WITHDRAWN

    Los Angeles, California, 90048, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    San Francisco, California, 94110, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Farmington, Connecticut, 06030, United States

  • Research Site

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Springfield, Illinois, 62702, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Baltimore, Maryland, 21287, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02111, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Boston, Massachusetts, 02115, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Rochester, Minnesota, 55902, United States

  • Research Site

    RECRUITING

    Olive Branch, Mississippi, 38654, United States

  • Research Site

    WITHDRAWN

    Kansas City, Missouri, 64151, United States

  • Research Site

    WITHDRAWN

    New York, New York, 10065, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Columbus, Ohio, 43210, United States

  • Research Site

    WITHDRAWN

    Portland, Oregon, 97239, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Bethlehem, Pennsylvania, 18017, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    RECRUITING

    Columbia, South Carolina, 29203, United States

  • Research Site

    WITHDRAWN

    Brownsville, Texas, 78526, United States

  • Research Site

    ACTIVE_NOT_RECRUITING

    Dallas, Texas, 75390, United States

  • Research Site

    RECRUITING

    Brisbane, 4102, Australia

  • Research Site

    RECRUITING

    Clayton, 3168, Australia

  • Research Site

    RECRUITING

    Perth, 6000, Australia

  • Research Site

    RECRUITING

    Calgary, Alberta, T2T 5C7, Canada

  • Research Site

    RECRUITING

    Ottawa, Ontario, K1H 7W9, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M4G 3E8, Canada

  • Research Site

    RECRUITING

    Montreal, Quebec, H4J 1C5, Canada

  • Research Site

    ACTIVE_NOT_RECRUITING

    Beijing, 100034, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Beijing, 100044, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Beijing, 100191, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Changsha, 430033, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Chengdu, 610041, China

  • Research Site

    WITHDRAWN

    Chengdu, 610500, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Chongqing, 400042, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Nanjing, 2100008, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Shanghai, 200025, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Tianjin, 300050, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Wuhan, 430030, China

  • Research Site

    COMPLETED

    Wuhan, 430060, China

  • Research Site

    RECRUITING

    Xianyang, 750004, China

  • Research Site

    ACTIVE_NOT_RECRUITING

    Amiens, 80054, France

  • Research Site

    ACTIVE_NOT_RECRUITING

    Bois-Guillaume, 76230, France

  • Research Site

    ACTIVE_NOT_RECRUITING

    Bordeaux, 33076, France

  • Research Site

    ACTIVE_NOT_RECRUITING

    Lille, 59037, France

  • Research Site

    WITHDRAWN

    Marseille, 13005, France

  • Research Site

    ACTIVE_NOT_RECRUITING

    Paris, 75018, France

  • Research Site

    ACTIVE_NOT_RECRUITING

    Paris, 75908, France

  • Research Site

    RECRUITING

    Berlin, 12203, Germany

  • Research Site

    RECRUITING

    Düsseldorf, 40225, Germany

  • Research Site

    RECRUITING

    Kaiserslautern, 67655, Germany

  • Research Site

    RECRUITING

    München, 80336, Germany

  • Research Site

    RECRUITING

    Reinfeld (Holstein), 23858, Germany

  • Research Site

    RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    ACTIVE_NOT_RECRUITING

    Belagavi, 590010, India

  • Research Site

    ACTIVE_NOT_RECRUITING

    Delhi, 110029, India

  • Research Site

    ACTIVE_NOT_RECRUITING

    Hyderabad, 500012, India

  • Research Site

    ACTIVE_NOT_RECRUITING

    Kolkata, 700020, India

  • Research Site

    WITHDRAWN

    Mumbai, 400008, India

  • Research Site

    ACTIVE_NOT_RECRUITING

    Mumbai, 400012, India

  • Research Site

    ACTIVE_NOT_RECRUITING

    Bologna, 40138, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Brescia, 25123, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Florence, 50134, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Milan, 20149, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Milan, 20162, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Torino, 10126, Italy

  • Research Site

    ACTIVE_NOT_RECRUITING

    Kawasaki-shi, 216-8511, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Kodaira-shi, 187-8510, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Minatoku, 108-8329, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Ōta-ku, 143-8541, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Shinjuku-ku, 162-8666, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Yokohama, 230-8765, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Yufu-shi, 879-5593, Japan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Barcelona, 08036, Spain

  • Research Site

    ACTIVE_NOT_RECRUITING

    Madrid, 28034, Spain

  • Research Site

    RECRUITING

    Madrid, 28040, Spain

  • Research Site

    ACTIVE_NOT_RECRUITING

    Madrid, 28046, Spain

  • Research Site

    RECRUITING

    Seville, 41013, Spain

  • Research Site

    WITHDRAWN

    Kaohsiung City, 80756, Taiwan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Taichung, 40705, Taiwan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Taipei, 10002, Taiwan

  • Research Site

    TERMINATED

    Taoyuan, 333, Taiwan

  • Research Site

    WITHDRAWN

    Yunlin, 640, Taiwan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Zhubei, 302, Taiwan

  • Research Site

    ACTIVE_NOT_RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    ACTIVE_NOT_RECRUITING

    Cardiff, CF14 4XW, United Kingdom

  • Research Site

    COMPLETED

    Dundee, DD1 9SY, United Kingdom

  • Research Site

    ACTIVE_NOT_RECRUITING

    London, EC1A 7BE, United Kingdom

  • Research Site

    ACTIVE_NOT_RECRUITING

    London, SE1 9RT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.